The advent of monoclonal antibody therapy, specifically trastuzumab, revolutionized the treatment of HER2-positive breast cancer by providing a targeted approach with enhanced efficacy and reduced toxicity compared to traditional therapies [14,15]. Here, ERBB2 is linked to breast cancer.